Moreover, we further validated the increased proportions of Treg cells, CD8+ T cells, and CD8+CD28- T cells and decreased CD4+ T cells and CD4/CD8 ratios in NSCLC patients at first relapse compared to newly diagnosed patients. This evidence concerns the gene CD8A and non-small cell lung carcinoma.